Home » Stocks » QBIO

Q BioMed Inc. (QBIO)

Stock Price: $0.8725 USD 0.0135 (1.57%)
Updated Jul 23, 2021 3:30 PM EDT - Market closed
Market Cap 24.38M
Revenue (ttm) 60,000
Net Income (ttm) -10.61M
Shares Out 27.59M
EPS (ttm) -0.44
PE Ratio n/a
Forward PE 109.89
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $0.8725
Previous Close $0.8590
Change ($) 0.0135
Change (%) 1.57%
Day's Open 0.8500
Day's Range 0.8500 - 0.8950
Day's Volume 39,595
52-Week Range 0.7700 - 1.9500

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK, July 12, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has recently entered into an exclusive license agreement with Clionix, a ...

2 weeks ago - PRNewsWire

Phoenix, Arizona--(Newsfile Corp. - June 23, 2021) - The Stock Day Podcast welcomed Q BioMed Inc. (OTCQB: QBIO) ("the Company"), a biotech acceleration and commercial stage company. CEO of the Company, ...

1 month ago - Newsfile Corp

Q BioMed Inc (OTCQB:QBIO) has hired WSI PBG LLC, which specializes in creating access for and selling pharmaceuticals, medical diagnostics, and durable medical equipment in the Veterans Administration, ...

2 months ago - Proactive Investors

NEW YORK, May 20, 2021 /PRNewswire/ --  Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has hired WSI PBG, LLC (WSI), a Michigan based firm specializing in creat...

2 months ago - PRNewsWire

Q BioMed Inc (OTCQB:QBIO) has unveiled its largest single investment so far, with Aedesius Holdings Ltd (AedesiusOne), a privately held global disruption aggregator, investing up to $30 million in the c...

2 months ago - Proactive Investors

NEW YORK, May 11, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB:  QBIO ), announced today that it has signed a securities purchase agreement ("Transaction") with Aedesius Holdings Ltd (AedesiusOne), a priva...

2 months ago - PRNewsWire

Q BioMed Inc (OTCQB:QBIO) has released a letter to shareholders, bringing them up to speed on the developments of its technology partner, Mannin Research, and its work to treat the coronavirus (COVID-19...

2 months ago - Proactive Investors

NEW YORK, April 27, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, updates shareholders. In March 2021,it was announced that our technology partner, Mannin Researc...

2 months ago - PRNewsWire

Acquires undervalued biomedical assets to accelerate their development Developing drugs and therapies to treat pediatric nonverbal autism, liver cancer, and glaucoma Produces cancer bone-pain drug Stron...

4 months ago - Proactive Investors

Q BioMed Inc (OTCQB:QBIO) has announced a supply contract with the US Department of Defense and Veterans Affairs (VA), which will make its cancer bone pain drug available to over 9 million VA beneficiar...

4 months ago - Proactive Investors

NEW YORK, March 2, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has signed an agreement for Strontium89 (Strontium Chloride Sr-89 Injecti...

4 months ago - PRNewsWire

NEW YORK, Feb. 1, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has been awarded a contract with UroGPO, the largest Group Purchasing Orga...

5 months ago - PRNewsWire

NEW YORK, Jan. 27, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), announced today that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug Designatio...

5 months ago - PRNewsWire

NEW YORK, Dec. 29, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, today issued a letter to shareholders. Dear Fellow Shareholders, As 2020 draws to a close, we joi...

6 months ago - PRNewsWire

NEW YORK, Dec. 21, 2020 /PRNewswire/ -- Q BioMed, Inc. (OTCQB: QBIO) is pleased to announce that its technology partner Mannin Research Inc. (MRI), a private Canadian biotechnology company, is a member ...

7 months ago - PRNewsWire

About QBIO

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89, a radiopharmaceutical therapeutic for the treatment of bone cancer pain therapies; and Metastron, a radiopharmaceutical drug for metastatic cancer bone pain therapy. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; ... [Read more...]

Industry
Biotechnology
Founded
2013
Stock Exchange
OTCMKTS
Ticker Symbol
QBIO
Full Company Profile

Financial Performance

Financial Statements